Previous Article | Next Article ![]()
Molecular and Cellular Biology, February 2004, p. 1758-1768, Vol. 24, No. 4
0270-7306/04/$08.00+0 DOI: 10.1128/MCB.24.4.1758-1768.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.
Department of Biomedical Science, College of Medicine, Florida State University, Tallahassee, Florida,1 Department of Internal Medicine I, University of Regensburg, Regensburg, Germany,2 Departments of Medicine, Biochemistry, and Biophysics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina,3 Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York 10032-37844
Received 30 April 2003/ Returned for modification 10 June 2003/ Accepted 3 November 2003
Cotranslational insertion of type I collagen chains into the lumen of the endoplasmic reticulum (ER) and their subsequent folding into a heterotrimeric helix is a complex process which requires coordinated action of the translation machinery, components of translocons, molecular chaperones, and modifying enzymes. Here we describe a role for the protein TRAM2 in collagen type I expression in hepatic stellate cells (HSCs) and fibroblasts. Activated HSCs are collagen-producing cells in the fibrotic liver. Quiescent HSCs produce trace amounts of type I collagen, while upon activation collagen synthesis increases 50- to 70-fold. Likewise, expression of TRAM2 dramatically increases in activated HSCs. TRAM2 shares 53% amino acid identity with the protein TRAM, which is a component of the translocon. However, TRAM2 has a C terminus with only a 15% identity. The C-terminal part of TRAM2 interacts with the Ca2+ pump of the ER, SERCA2b, as demonstrated in a Saccharomyces cerevisiae two-hybrid screen and by immunoprecipitations in human cells. TRAM2 also coprecipitates with anticollagen antibody, suggesting that these two proteins interact. Deletion of the C-terminal part of TRAM2 inhibits type I collagen synthesis during activation of HSCs. The pharmacological inhibitor of SERCA2b, thapsigargin, has a similar effect. Depletion of ER Ca2+ with thapsigargin results in inhibition of triple helical collagen folding and increased intracellular degradation. We propose that TRAM2, as a part of the translocon, is required for the biosynthesis of type I collagen by coupling the activity of SERCA2b with the activity of the translocon. This coupling may increase the local Ca2+ concentration at the site of collagen synthesis, and a high Ca2+ concentration may be necessary for the function of molecular chaperones involved in collagen folding.
This article has been cited by other articles:
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»